With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.25637-16-5,4-Bromotetrahydropyran,as a common compound, the synthetic route is as follows.
[00497] To a solution of 122-1 (50.0 mg, 0.16 mmol, 1. 0 eq) in DMF (5.0 mL) was added K2C03 (45.23 mg, 0.33 mmol, 2.0 eq) and 122-2 (32.4 mg, 0.120 mmol, 1.2 eq). The mixture was stirred at 100 C for 24 hours under an N2 atmosphere. LCMS showed the desired compound was formed. The reaction was filtered to give a crude product. The crude product was purified by prep-HPLC to give the title compound (27.33 mg, 70.19 umol, 42.85% yield). LCMS (ESI): RT = 0.932 min, mass calc. for Ci9Hi8F3N50 389.15, m/z found 390.0[M+H]+; 1HNMR (400 MHz, CDCl3-i 9.08 (s, 1H), 8.21 (dd, J= 1.4, 7.9 Hz, 1H), 7.54 (d, J= 8.5 Hz, 3H), 7.41- 7.35 (m, 1H), 7.29 (d, J= 8.5 Hz, 2H), 7.05 (t, J= 7.3Hz, 1H), 5.07 – 4.95 (m, 1H), 4.16 (td, J= 3.3, 12.0 Hz, 2H), 3.64 (dt, J = 2.3, 11.5 Hz, 2H), 2.46 – 2.24 (m, 4H).
25637-16-5, 25637-16-5 4-Bromotetrahydropyran 13349654, aTetrahydropyrans compound, is more and more widely used in various fields.
Reference£º
Patent; VIVACE THERAPEUTICS, INC.; KONRADI, Andrei W.; LIN, Tracy Tzu-Ling Tang; (396 pag.)WO2018/204532; (2018); A1;,
Tetrahydropyran – Wikipedia
Tetrahydropyran – an overview | ScienceDirect Topics